Abstract 8936: CXCR6 Blockade is a Powerful Therapy for Immune Checkpoint Inhibitor Induced Myocarditis
Circulation · 02.11.2026 · 154 (Suppl_1)
DOI: 10.1161/circ.154.suppl_1.8936 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Lihong Pan und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Aims
Immune checkpoint inhibitor (ICI)-associated myocarditis is a rare but often fatal immune-related adverse event characterized by myocardial inflammation, cardiac dysfunction, and life-threatening arrhythmias. Effective targeted therapies remain lacking. This study aimed to identify key immune drivers of ICI-induced myocarditis and evaluate the therapeutic potential of targeting the C-X-C motif chemokine receptor 6 (CXCR6) pathway. Methods and Results: Using single-cell RNA sequencing, flow cytometry, electrocardiographic and histological analyses, we investigated immune mechanisms in cytotoxic T-lymphocyte-associated protein 4 heterozygous and programmed cell death protein 1 deficient (Ctla4 + / − ; Pdcd1 − / − ) mice, a model of severe ICI-associated myocarditis. ICI-induced myocarditis resulted in extensive myocardial leukocyte infiltration, cardiac inflammation, conduction abnormalities, arrhythmias, and high mortality. Single-cell transcriptomic profiling revealed a marked expansion of CXCR6 high CD8 + T cells accompanied by increased expression of the CXCR6 ligand CXCL16 in cardiac macrophages. Flow cytometric analysis confirmed substantial accumulation of CXCR6 + CD8 + T cells and CXCL16 + macrophages within the myocardium, with CXCR6 + CD8 + T cells exhibiting a CD44 + effector phenotype. Therapeutic CXCR6 blockade significantly improved survival and reduced myocardial immune cell infiltration in both male and female mice. Furthermore, CXCR6 inhibition attenuated CD8 + T-cell effector activation, reduced IFN-γ and TNF-α production, and decreased granzyme B and perforin expression. Importantly, CXCR6 blockade mitigated cardiac electrical abnormalities and arrhythmias associated with myocarditis. In addition, CXCR6 inhibition reduced cardiac macrophage accumulation, downregulated macrophage MHC class I expression, and suppressed CXCL16 expression, thereby disrupting pathogenic immune crosstalk within the myocardium.
Conclusions
These findings identify the CXCR6-CXCL16 axis as a central mediator of pathogenic immune responses in ICI-associated myocarditis and demonstrate that CXCR6 blockade effectively suppresses myocardial inflammation, reduces arrhythmogenic cardiac injury, and improves survival. Targeting CXCR6 represents a promising therapeutic strategy for the treatment of ICI-mediated myocarditis. Keywords: CXCR6; immune checkpoint inhibitor; myocarditis; arrhythmia; CD8 + T cells; macrophages.
Zitieren
APA
Pan, L., Wang, D., He, X., & Chen, Y. (2026). Abstract 8936: CXCR6 Blockade is a Powerful Therapy for Immune Checkpoint Inhibitor Induced Myocarditis. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.8936
Vancouver
Pan L, Wang D, He X, Chen Y. Abstract 8936: CXCR6 Blockade is a Powerful Therapy for Immune Checkpoint Inhibitor Induced Myocarditis. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.8936
BibTeX
@article{Pan2026,
author = {Pan, Lihong and Wang, Dongzhi and He, Xiaochen and Chen, Yingjie},
title = {Abstract 8936: CXCR6 Blockade is a Powerful Therapy for Immune Checkpoint Inhibitor Induced Myocarditis},
journal = {Circulation},
year = {2026},
volume = {154},
number = {Suppl_1},
doi = {10.1161/circ.154.suppl_1.8936}
}
EUVIMED